Mereo BioPharma Group/$MREO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Mereo BioPharma Group
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Ticker
$MREO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
36
ISIN
US5894921072
Website
MREO Metrics
BasicAdvanced
$366M
-
-$0.31
0.47
-
Price and volume
Market cap
$366M
Beta
0.47
52-week high
$5.02
52-week low
$1.58
Average daily volume
1.6M
Financial strength
Current ratio
8.923
Quick ratio
8.587
Total debt to equity
1.243
Interest coverage (TTM)
-38.15%
Management effectiveness
Return on assets (TTM)
-47.59%
Return on equity (TTM)
-91.70%
Valuation
Price to book
6.09
Price to tangible book (TTM)
6.14
Price to free cash flow (TTM)
-10.402
Growth
Earnings per share change (TTM)
59.81%
3-year earnings per share growth (CAGR)
-7.54%
What the Analysts think about MREO
Analyst ratings (Buy, Hold, Sell) for Mereo BioPharma Group stock.
MREO Financial Performance
Revenues and expenses
MREO Earnings Performance
Company profitability
MREO News
AllArticlesVideos
Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights
GlobeNewsWire·1 week ago
Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights
GlobeNewsWire·2 months ago
Hidden Gems: 5 Stocks Under $10 With Massive Growth Potential
MarketBeat·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Mereo BioPharma Group stock?
Mereo BioPharma Group (MREO) has a market cap of $366M as of May 21, 2025.
What is the P/E ratio for Mereo BioPharma Group stock?
The price to earnings (P/E) ratio for Mereo BioPharma Group (MREO) stock is 0 as of May 21, 2025.
Does Mereo BioPharma Group stock pay dividends?
No, Mereo BioPharma Group (MREO) stock does not pay dividends to its shareholders as of May 21, 2025.
When is the next Mereo BioPharma Group dividend payment date?
Mereo BioPharma Group (MREO) stock does not pay dividends to its shareholders.
What is the beta indicator for Mereo BioPharma Group?
Mereo BioPharma Group (MREO) has a beta rating of 0.47. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.